Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ProQR Therapeutics (PRQR) Short term Debt (2016 - 2025)

ProQR Therapeutics' Short term Debt history spans 6 years, with the latest figure at $5.7 million for Q4 2025.

  • On a quarterly basis, Short term Debt rose 15.83% to $5.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.7 million, a 15.83% increase, with the full-year FY2025 number at $5.7 million, up 15.83% from a year prior.
  • Short term Debt hit $5.7 million in Q4 2025 for ProQR Therapeutics, up from $4.9 million in the prior quarter.
  • Over the last five years, Short term Debt for PRQR hit a ceiling of $43.1 million in Q1 2022 and a floor of $19910.1 in Q1 2021.
  • Historically, Short term Debt has averaged $12.2 million across 5 years, with a median of $4.9 million in 2024.
  • Biggest five-year swings in Short term Debt: soared 216181.09% in 2022 and later crashed 90.34% in 2023.
  • Tracing PRQR's Short term Debt over 5 years: stood at $5.5 million in 2021, then plummeted by 53.27% to $2.6 million in 2022, then rose by 23.39% to $3.1 million in 2023, then surged by 55.58% to $4.9 million in 2024, then grew by 15.83% to $5.7 million in 2025.
  • Business Quant data shows Short term Debt for PRQR at $5.7 million in Q4 2025, $4.9 million in Q4 2024, and $3.1 million in Q3 2023.